Comparative efficacy of tofisopam and placebo.
Tofisopam is a new agent marketed in Europe as a minor tranquilizer. The authors conducted a 4-week double-blind trial of this drug compared with placebo in 57 outpatients with anxiety and depression. They found that according to physician ratings and patient self-ratings tofisopam was an effective anxiolytic agent for subjects with anxiety and depression. Twenty-one percent of the patients receiving tofisopam and 10% of those receiving placebo reported side effects. The drug was especially effective in the treatment of somatic difficulties.
D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy*; D001569:Benzodiazepines; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy*; D006801:Humans; D011581:Psychological Tests; D011602:Psychophysiologic Disorders / Q000188:drug therapy*
D014151:Anti-Anxiety Agents; D001569:Benzodiazepines; C012582:tofisopam